Abstract:BACKGROUND Gliomas pose a significant challenge to effective treatment despite advancements in chemotherapy and radiotherapy. Glioma stem cells (GSCs), a subset within tumors, contribute to resistance, tumor heterogeneity, and plasticity. Recent studies reveal GSCs' role in therapeutic resistance, driven by DNA repair mechanisms and dynamic transitions between cellular states. Resistance mechanisms can involve different cellular pathways, most of which have been recently reported in the literature. Despite progress, targeted therapeutic approaches lack consensus due to GSCs' high plasticity. AIM To analyze targeted therapies against GSC-mediated resistance to radio- and chemotherapy in gliomas, focusing on underlying mechanisms. METHODS A systematic search was conducted across major medical databases (PubMed, Embase, and Cochrane Library) up to September 30, 2023. The search strategy utilized relevant Medical Subject Heading terms and keywords related to including "glioma stem cells", "radiotherapy", "chemotherapy", "resistance", and "targeted therapies". Studies included in this review were publications focusing on targeted therapies against the molecular mechanism of GSC-mediated resistance to radiotherapy resistance (RTR). RESULTS In a comprehensive review of 66 studies on stem cell therapies for SCI, 452 papers were initially identified, with 203 chosen for full-text analysis. Among them, 201 were deemed eligible after excluding 168 for various reasons. The temporal breakdown of studies illustrates this trend: 2005-2010 (33.3%), 2011-2015 (36.4%), and 2016-2022 (30.3%). Key GSC models, particularly U87 (33.3%), U251 (15.2%), and T98G (15.2%), emerge as significant in research, reflecting their representativeness of glioma characteristics. Pathway analysis indicates a focus on phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (mTOR) (27.3%) and Notch (12.1%) pathways, suggesting their crucial roles in resistance development. Targeted molecules with mTOR (18.2%), CHK1/2 (15.2%), and ATP binding cassette G2 (12.1%) as frequent targets underscore their importance in overcoming GSC-mediated resistance. Various therapeutic agents, notably RNA inhibitor/short hairpin RNA (27.3%), inhibitors (e.g., LY294002, NVP-BEZ235) (24.2%), and monoclonal antibodies (e.g., cetuximab) (9.1%), demonstrate versatility in targeted therapies. among 20 studies (60.6%), the most common effect on the chemotherapy resistance response is a reduction in temozolomide resistance (51.5%), followed by reductions in carmustine resistance (9.1%) and doxorubicin resistance (3.0%), while resistance to RTR is reduced in 42.4% of studies. CONCLUSION GSCs play a complex role in mediating radioresistance and chemoresistance, emphasizing the necessity for precision therapies that consider the heterogeneity within the GSC population and the dynamic tumor microenvironment to enhance outcomes for glioblastoma patients.

Radiation and Glioma Immune Escape

Recent Advances in the Radiotherapy of Gliomas

Research Progress on Radiotherapy Technology and Dose Fraction Scheme for Advanced Gliomas

Radiation Induced Metabolic Alterations Associate With Tumor Aggressiveness and Poor Outcome in Glioblastoma

Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution

Irradiation induces glioblastoma cell senescence and senescence-associated secretory phenotype

The adaptive transition of glioblastoma stem cells and its implications on treatments

Nanoradiosensitizers in glioblastoma treatment: recent advances and future perspectives

Radiotherapy‐Induced Astrocyte Senescence Promotes an Immunosuppressive Microenvironment in Glioblastoma to Facilitate Tumor Regrowth

Molecular mechanisms of tumor resistance to radiotherapy

Immunotherapy for Recurrent Glioma-From Bench to Bedside

The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma

Application of New Radiosensitizer Based on Nano-Biotechnology in the Treatment of Glioma

Elimination of Radiation-Induced Senescence in the Brain Tumor Microenvironment Attenuates Glioblastoma Recurrence

Radiation-induced senescence in glioblastoma: An overview of the mechanisms and eradication strategies

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

Role of glioma stem cells in promoting tumor chemo- and radioresistance: A systematic review of potential targeted treatments

Advance of Immune Checkpoint Inhibitors and Clinical Trials in Glioma

Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes

Biological Insights and Radiation–Immuno–Oncology Developments in Primary and Secondary Brain Tumors

Radiotherapeutic advances in the management of glioblastoma